#182 : Pharmacokinetics of Ovarian Stimulation for Projected Poor Responder Patients in IVF. A Randomised Trial Comparing a Corifollitropin Alfa Agonist Flare Protocol with a Corifollitropin Alfa Antagonist Protocol
Background & Aims: Approximately 10% of patients have a sub-optimal response to controlled ovarian stimulation. Many different protocols for superovulation have been developed for this group of patients but the optimal approach for “poor responder” patients is yet to be determined. Use of corifo...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
World Scientific Publishing
2023-12-01
|
| Series: | Fertility & Reproduction |
| Online Access: | https://www.worldscientific.com/doi/10.1142/S2661318223741620 |
| _version_ | 1797237043794804736 |
|---|---|
| author | Kaushalya Arulpragasam Mary O’Neil Prudence Sweeten Devora Lieberman Rachael Rodgers Shannon Choi Joan Tan Nancy Briggs William L. Ledger |
| author_facet | Kaushalya Arulpragasam Mary O’Neil Prudence Sweeten Devora Lieberman Rachael Rodgers Shannon Choi Joan Tan Nancy Briggs William L. Ledger |
| author_sort | Kaushalya Arulpragasam |
| collection | DOAJ |
| description | Background & Aims: Approximately 10% of patients have a sub-optimal response to controlled ovarian stimulation. Many different protocols for superovulation have been developed for this group of patients but the optimal approach for “poor responder” patients is yet to be determined. Use of corifollitropin alfa (Elonva) in a flare (EF) protocol is a novel approach to ovarian stimulation for predicted poor responder patients. We hypothesised that the unique pharmacokinetic and pharmacodynamic profiles of corifollitropin alfa would maximise FSH exposure and follicular recruitment in the critical early follicular phase due to the initial suprathreshold release of bioactive FSH in the initial 2-3 days of exposure to Elonva, in combination with the ‘flare’ of endogenous FSH release. Method: Twenty-one women aged 31-41 were identified as predicted poor responder patients according to the Poseidon criteria. Each participant was randomised to treatment with Elonva/Synarel flare or Elonva/Orgalutran antagonist. Serum FSH and E2 were measured daily for five days following injection of Elonva. The study was approved by the Southeastern Sydney HREC. Results: Serum FSH concentrations were significantly higher at each time point in the EF group when compared with the antagonist group (p=0.022). Peak FSH two days after injection of Elonva, was also significantly higher 27 vs 11 IU/L. Serum E2 concentrations were also significantly higher in the EF group at each time point (p=0.039). On day seven of stimulation, E2 concentrations were 3000 vs 1850 pmol/L. Conclusion: The corifollitropin alfa agonist flare protocol produces significantly higher FSH and E2 concentrations than a standard corifollitropin alfa antagonist protocol for projected poor responder patients, with reduced patient burden for a group who may need multiple ovarian stimulation cycles to achieve a pregnancy. A larger RCT is required to study embryology and pregnancy outcomes, costs and patient burden. |
| first_indexed | 2024-04-24T17:13:29Z |
| format | Article |
| id | doaj.art-181183666dba40e58bf4d574c6797818 |
| institution | Directory Open Access Journal |
| issn | 2661-3182 2661-3174 |
| language | English |
| last_indexed | 2024-04-24T17:13:29Z |
| publishDate | 2023-12-01 |
| publisher | World Scientific Publishing |
| record_format | Article |
| series | Fertility & Reproduction |
| spelling | doaj.art-181183666dba40e58bf4d574c67978182024-03-28T07:54:18ZengWorld Scientific PublishingFertility & Reproduction2661-31822661-31742023-12-01050435835810.1142/S2661318223741620#182 : Pharmacokinetics of Ovarian Stimulation for Projected Poor Responder Patients in IVF. A Randomised Trial Comparing a Corifollitropin Alfa Agonist Flare Protocol with a Corifollitropin Alfa Antagonist ProtocolKaushalya Arulpragasam0Mary O’Neil1Prudence Sweeten2Devora Lieberman3Rachael Rodgers4Shannon Choi5Joan Tan6Nancy Briggs7William L. Ledger8Fertility and Research Centre, Randwick, AustraliaUniversity of New South Wales, Randwick, AustraliaFertility and Research Centre, Randwick, AustraliaCity Fertilty Centre, Sydney, AustraliaFertility and Research Centre, Randwick, AustraliaUniversity of New South Wales, Randwick, AustraliaUniversity of New South Wales, Randwick, AustraliaUniversity of New South Wales, Randwick, AustraliaFertility and Research Centre, Randwick, AustraliaBackground & Aims: Approximately 10% of patients have a sub-optimal response to controlled ovarian stimulation. Many different protocols for superovulation have been developed for this group of patients but the optimal approach for “poor responder” patients is yet to be determined. Use of corifollitropin alfa (Elonva) in a flare (EF) protocol is a novel approach to ovarian stimulation for predicted poor responder patients. We hypothesised that the unique pharmacokinetic and pharmacodynamic profiles of corifollitropin alfa would maximise FSH exposure and follicular recruitment in the critical early follicular phase due to the initial suprathreshold release of bioactive FSH in the initial 2-3 days of exposure to Elonva, in combination with the ‘flare’ of endogenous FSH release. Method: Twenty-one women aged 31-41 were identified as predicted poor responder patients according to the Poseidon criteria. Each participant was randomised to treatment with Elonva/Synarel flare or Elonva/Orgalutran antagonist. Serum FSH and E2 were measured daily for five days following injection of Elonva. The study was approved by the Southeastern Sydney HREC. Results: Serum FSH concentrations were significantly higher at each time point in the EF group when compared with the antagonist group (p=0.022). Peak FSH two days after injection of Elonva, was also significantly higher 27 vs 11 IU/L. Serum E2 concentrations were also significantly higher in the EF group at each time point (p=0.039). On day seven of stimulation, E2 concentrations were 3000 vs 1850 pmol/L. Conclusion: The corifollitropin alfa agonist flare protocol produces significantly higher FSH and E2 concentrations than a standard corifollitropin alfa antagonist protocol for projected poor responder patients, with reduced patient burden for a group who may need multiple ovarian stimulation cycles to achieve a pregnancy. A larger RCT is required to study embryology and pregnancy outcomes, costs and patient burden.https://www.worldscientific.com/doi/10.1142/S2661318223741620 |
| spellingShingle | Kaushalya Arulpragasam Mary O’Neil Prudence Sweeten Devora Lieberman Rachael Rodgers Shannon Choi Joan Tan Nancy Briggs William L. Ledger #182 : Pharmacokinetics of Ovarian Stimulation for Projected Poor Responder Patients in IVF. A Randomised Trial Comparing a Corifollitropin Alfa Agonist Flare Protocol with a Corifollitropin Alfa Antagonist Protocol Fertility & Reproduction |
| title | #182 : Pharmacokinetics of Ovarian Stimulation for Projected Poor Responder Patients in IVF. A Randomised Trial Comparing a Corifollitropin Alfa Agonist Flare Protocol with a Corifollitropin Alfa Antagonist Protocol |
| title_full | #182 : Pharmacokinetics of Ovarian Stimulation for Projected Poor Responder Patients in IVF. A Randomised Trial Comparing a Corifollitropin Alfa Agonist Flare Protocol with a Corifollitropin Alfa Antagonist Protocol |
| title_fullStr | #182 : Pharmacokinetics of Ovarian Stimulation for Projected Poor Responder Patients in IVF. A Randomised Trial Comparing a Corifollitropin Alfa Agonist Flare Protocol with a Corifollitropin Alfa Antagonist Protocol |
| title_full_unstemmed | #182 : Pharmacokinetics of Ovarian Stimulation for Projected Poor Responder Patients in IVF. A Randomised Trial Comparing a Corifollitropin Alfa Agonist Flare Protocol with a Corifollitropin Alfa Antagonist Protocol |
| title_short | #182 : Pharmacokinetics of Ovarian Stimulation for Projected Poor Responder Patients in IVF. A Randomised Trial Comparing a Corifollitropin Alfa Agonist Flare Protocol with a Corifollitropin Alfa Antagonist Protocol |
| title_sort | 182 pharmacokinetics of ovarian stimulation for projected poor responder patients in ivf a randomised trial comparing a corifollitropin alfa agonist flare protocol with a corifollitropin alfa antagonist protocol |
| url | https://www.worldscientific.com/doi/10.1142/S2661318223741620 |
| work_keys_str_mv | AT kaushalyaarulpragasam 182pharmacokineticsofovarianstimulationforprojectedpoorresponderpatientsinivfarandomisedtrialcomparingacorifollitropinalfaagonistflareprotocolwithacorifollitropinalfaantagonistprotocol AT maryoneil 182pharmacokineticsofovarianstimulationforprojectedpoorresponderpatientsinivfarandomisedtrialcomparingacorifollitropinalfaagonistflareprotocolwithacorifollitropinalfaantagonistprotocol AT prudencesweeten 182pharmacokineticsofovarianstimulationforprojectedpoorresponderpatientsinivfarandomisedtrialcomparingacorifollitropinalfaagonistflareprotocolwithacorifollitropinalfaantagonistprotocol AT devoralieberman 182pharmacokineticsofovarianstimulationforprojectedpoorresponderpatientsinivfarandomisedtrialcomparingacorifollitropinalfaagonistflareprotocolwithacorifollitropinalfaantagonistprotocol AT rachaelrodgers 182pharmacokineticsofovarianstimulationforprojectedpoorresponderpatientsinivfarandomisedtrialcomparingacorifollitropinalfaagonistflareprotocolwithacorifollitropinalfaantagonistprotocol AT shannonchoi 182pharmacokineticsofovarianstimulationforprojectedpoorresponderpatientsinivfarandomisedtrialcomparingacorifollitropinalfaagonistflareprotocolwithacorifollitropinalfaantagonistprotocol AT joantan 182pharmacokineticsofovarianstimulationforprojectedpoorresponderpatientsinivfarandomisedtrialcomparingacorifollitropinalfaagonistflareprotocolwithacorifollitropinalfaantagonistprotocol AT nancybriggs 182pharmacokineticsofovarianstimulationforprojectedpoorresponderpatientsinivfarandomisedtrialcomparingacorifollitropinalfaagonistflareprotocolwithacorifollitropinalfaantagonistprotocol AT williamlledger 182pharmacokineticsofovarianstimulationforprojectedpoorresponderpatientsinivfarandomisedtrialcomparingacorifollitropinalfaagonistflareprotocolwithacorifollitropinalfaantagonistprotocol |